More importantly, this inhibitory effect was significantly pronounced from 2 weeks after TAM administration compared to combination treatment with GTPs and BSp (p < 0.001) suggesting that this novel dietary combination regimen enhances the anti-tumor properties of TAM by re-sensitizing ERα-negative breast cancer to anti-hormone therapy. The gene discussed is ESR1; the disease is breast carcinoma.